Delgocitinib 2% Cream Therapeutic Cheat Sheet
Delgocitinib is a topical pan-Janus kinase (JAK) inhibitor that represents a novel non-steroidal treatment mechanism for chronic hand dermatitis. As a pan-JAK inhibitor, delgocitinib blocks all four members of the JAK family (JAK1, JAK2, JAK3, and tyrosine kinase 2 (TYK2)), thus simultaneously modulating the many cytokine pathways that drive chronic inflammatory skin disorders. Delgocitinib was in …
Delgocitinib is a topical pan-Janus kinase (JAK) inhibitor that represents a novel non-steroidal treatment mechanism for chronic hand dermatitis. As a pan-JAK inhibitor, delgocitinib blocks all four members of the JAK family (JAK1, JAK2, JAK3, and tyrosine kinase 2 (TYK2)), thus simultaneously modulating the many cytokine pathways that drive chronic inflammatory skin disorders. Delgocitinib was in … Continue reading "Delgocitinib 2% Cream Therapeutic Cheat Sheet"
Abrocitinib is an oral, once-daily selective Janus kinase 1 (JAK1) inhibitor approved for moderate-to-severe atopic dermatitis. It can provide rapid improvement in pruritus and skin disease and is a useful treatment option for many patients. As an oral medication, it may also be preferred by patients who want to avoid injections. When prescribing abrocitinib, it is important to discuss laboratory … 
Lebrikizumab is a humanized immunoglobulin G4 (IgG4) monoclonal antibody that selectively targets IL-13, a key cytokine implicated in the pathogenesis of type 2 inflammatory diseases.1 Lebrikizumab binds IL-13 with high affinity and a slow dissociation rate, which prevents heterodimerization of the IL-13 receptor alpha-1 subunit (IL-13Rα1) with the IL-4 receptor alpha (IL-4Rα) signaling complex. … 
Atopic dermatitis and prurigo nodularis are chronic, life-altering diseases with a common feature of debilitating pruritus that significantly impacts our patients’ qualities of life. For those with resistant and extensive disease, dermatologists now have nemolizumab in our armamentarium, the first FDA approved IL-31 inhibitor. We continue our series, Therapeutic Cheat Sheet, with a closer look a …